Wandercraft’s person exoskeleton, Eve, offers upright motion and walking independence for people with severe mobility disabilities. | Source: Wandercraft
Wandercraft has raised $75 million in Series D funding. The French robotics company said the new funding will help it commercialize the Eve self-balancing personal exoskeleton as early as 2026. Wandercraft said it also wants to expand clinical adoption of its flagship rehabilitation system, Atalante X, and develop and deploy Calvin-40, its new humanoid.
“The momentum we’ve achieved over the past few years is extraordinary,” said Matthieu Masselin, CEO and co-founder of Wandercraft. “We’ve expanded globally, launched pivotal clinical trials, readied the commercialization of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group. This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”
Wandercraft said its technology is powered by AI that has been refined through billions of simulations and tens of millions of real-world steps.
In February, Wandercraft started a clinical trial of its personal exoskeleton. The self-balancing exoskeleton is designed to offer upright motion and walking independence for individuals with severe mobility impairments, providing the benefits of standing, walking, bending, reaching, and restoring the feeling of natural walking motion to everyday life.
Save now with early bird discount
The clinical trial is being conducted at the James J. Peters VA Medical Center in the Bronx, NY. Wandercraft said another clinical trial will soon start at the Kessler Institute for Rehabilitation in West Orange, NJ. The study will assess the safety and effectiveness of the Personal Exoskeleton for individuals with spinal cord injuries (SCI).
During the 2024 Olympics, Wandercraft’s Personal Exoskeleton helped carry the Olympic torch as part of the traditional relay. Kevin Piette, who typically uses a wheelchair, became the first user of a self-balancing exoskeleton to walk in torch relay before the Olympics, the company claimed.
The round included major contributions from Renault Group, PSIM fund, managed on behalf of the French State by Bpifrance as part of the France 2030 plan, Teampact Ventures, and Quadrant Management. Other participants in the Series D round include LBO France, Mutuelles Impact – Managed by XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.
Wandercraft builds momentum for scaling robotics
Wandercraft last week announced that Renault Group took a minority stake in the company. The company said the partnership will give it access to Renault Group’s industrial expertise to scale production of Wandercraft’s exoskeletons and industrial robots.
Wandercraft said this lays the groundwork for cost-efficient scaling of Eve and the broader Calvin humanoid family. Renault Group is also Wandercraft’s first commercial partner and customer of Calvin-40, named for its development time of just 40 days, the company claimed.
Calvin-40 is an industrial-grade humanoid intended for physically-demanding tasks. The robot’s development was made possible by using Wandercraft’s rapid development process and existing leading-edge robotics platform integrated with NVIDIA Isaac technologies, including the NVIDIA Isaac GR00T N1 foundation model and the NVIDIA Jetson edge AI platform, it said.
Tell Us What You Think!